Lessons from immunotherapies in multiple sclerosis

Rispoli, Marianna Gabriella; D’Apolito, Maria; Pozzilli, Valeria; Tomassini, Valentina

doi:10.1016/b978-0-323-85555-6.00013-8

Cited by 1 publication

(2 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic biomarkers involve the identification of genetic variants associated with increased risk of MS or disease progression. Epigenetic biomarkers involve the analysis of DNA methylation patterns that can be used to predict disease course and treatment response (12). Proteomic biomarkers involve the analysis of protein expression patterns that can be used to diagnose and monitor disease.…”

Section: Precision Diagnostics In Multiple Sclerosis: Biomarkers and ...mentioning

confidence: 99%

“…For example, monoclonal antibodies targeting CD20, such as rituximab and ocrelizumab, have been shown to reduce B-cell activity and disease activity in MS. Similarly, monoclonal antibodies targeting alpha-4 integrin, such as natalizumab and vedolizumab, have been shown to reduce T-cell activity and disease activity in MS (12,19). Other targeted therapies, such as sphingosine-1-phosphate receptor modulators, have been shown to reduce lymphocyte migration and prevent further CNS damage.…”

Section: Targeted Therapies In Multiple Sclerosis: Role Of Precision ...mentioning

confidence: 99%

See 1 more Smart Citation

Personalized Treatment for Multiple Sclerosis: The Role of Precision Medicine

Pathak

2023

View full text Add to dashboard Cite

Multiple Sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central nervous system. It is a complex and heterogeneous disease, and its pathogenesis is still not completely understood. Precision medicine, which involves the use of advanced technologies such as genomics, proteomics, metabolomics, and imaging to identify specific biomarkers and disease subtypes, is a promising approach to the management of multiple sclerosis. Precision medicine in MS includes the development of targeted therapies that aim to modulate specific immune pathways involved in MS pathogenesis. This review article aims to provide an overview of the current status and future directions of precision medicine in MS. The article discusses the importance of precision diagnostics in MS, including the identification of biomarkers and imaging techniques for MS, as well as the challenges and opportunities of personalized treatment in MS. Targeted therapies in MS are also discussed, including the challenges of developing and implementing these therapies. The article highlights the potential of combination therapies in MS, and the role of AI and ML in improving biomarker identification. The challenges of implementing precision medicine in clinical practice are also addressed, including the standardization of diagnostic criteria and treatment guidelines, and the ethical and legal considerations of personalized treatment. Overall, precision medicine represents a promising approach to the management of MS, with the potential to improve diagnosis, prognosis, and treatment outcomes. However, the implementation of precision medicine in MS clinical practice requires addressing several challenges, including the standardization of diagnostic criteria and treatment guidelines, and the development of affordable and accessible technologies and therapies. With continued research and advances in technology, precision medicine has the potential to transform the field of MS research and clinical practice.

show abstract

Section: Precision Diagnostics In Multiple Sclerosis: Biomarkers and ...mentioning

confidence: 99%

Section: Targeted Therapies In Multiple Sclerosis: Role Of Precision ...mentioning

confidence: 99%